Article Text

Download PDFPDF

Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease
  1. C Ribi1,
  2. R Sztajzel2,
  3. J Delavelle3,
  4. C Chizzolini1
  1. 1Clinical Immunology and Allergy, Department of Internal Medicine, University Hospital Geneva, Geneva, Switzerland
  2. 2Department of Neurology, University Hospital Geneva, Geneva, Switzerland
  3. 3Department of Radiology, University Hospital Geneva, Geneva, Switzerland
  1. Correspondence to:
 Camillo Ribi
 Clinical Immunology and Allergy, Department of Internal Medicine, University Hospital Geneva, Geneva, Switzerland;


Behçet disease is a chronic relapsing inflammatory condition, predominantly affecting young adults, characterised by recurrent bipolar aphtae and systemic manifestations for which tumour necrosis factor (TNF) α blockade has recently emerged as an effective treatment. We report the case of a patient presenting with mucocutaneous and ocular manifestations who in the course of his disease developed CNS parenchymal involvement. While being treated with pulsed cyclophosphamide and corticosteroids, he suffered a relapse of his CNS involvement that was efficaciously controlled by infliximab. No disease activity was observed during a full year of TNF blockade, associated with azathioprine, colchicine, and corticosteroids. However, 7 months after the last administration of infliximab and still under immunosuppressant agents, CNS lesions recurred. Infliximab was successfully reintroduced and since continued with no side effects. The sequence of events observed in this patient suggests that TNF blockade is efficacious in suppressing neuro-Behçet disease and once introduced should be maintained for a prolonged period of time.

  • BBB, blood-brain barrier
  • BD, Behçet disease
  • MRI, magnetic resonance imaging
  • NB, neuro-Behçet disease
  • TNF, tumour necrosis factor
  • Behçet disease
  • cerebral vasculitis
  • meningoencephalitis
  • TNF-alpha
View Full Text

Statistics from


  • Competing interests: none declared

  • The patient detailed in this study agreed to his details being published.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.